![Konstantin Bloch](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Konstantin Bloch
Corporate Officer/Principal bei Felsenstein Medical Research Center
Profil
Dr. Konstantin Bloch is Head-Diabetes & Obesity Research Laboratory at Felsenstein Medical Research Center.
Dr. Bloch was previously employed as Co-Founder by Beta-O2 Technologies Ltd.
and Senior Scientist by Tel-Aviv University.
He received his undergraduate degree from Kharkov National University and a doctorate degree from Russian Academy of Sciences.
Aktive Positionen von Konstantin Bloch
Unternehmen | Position | Beginn |
---|---|---|
Felsenstein Medical Research Center | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Konstantin Bloch
Unternehmen | Position | Ende |
---|---|---|
Tel-Aviv University
![]() Tel-Aviv University Other Consumer ServicesConsumer Services Tel-Aviv University operates as a university in Israel. Its faculties include arts, engineering, science, humanities, law, life science, management, medicine, and social science. The company was founded in 1956 and is headquartered in Ramat Aviv, Israel. | Corporate Officer/Principal | - |
Beta-O2 Technologies Ltd.
![]() Beta-O2 Technologies Ltd. Medical SpecialtiesHealth Technology Beta-O2 Technologies Ltd. develops implantable bio-artificial pancreas devices. It offers BAir, a bio-artificial pancreas that provides a viable environment for islets of Langerhans to thrive and provide the body with insulin on demand. The company was founded by Pnina Vardi, Konstantin Bloch, and Yossi Gross in 2004 and is headquartered in Rosh-Haayin, Israel. | Gründer | - |
Ausbildung von Konstantin Bloch
Kharkiv National University | Undergraduate Degree |
Russian Academy of Sciences | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Beta-O2 Technologies Ltd.
![]() Beta-O2 Technologies Ltd. Medical SpecialtiesHealth Technology Beta-O2 Technologies Ltd. develops implantable bio-artificial pancreas devices. It offers BAir, a bio-artificial pancreas that provides a viable environment for islets of Langerhans to thrive and provide the body with insulin on demand. The company was founded by Pnina Vardi, Konstantin Bloch, and Yossi Gross in 2004 and is headquartered in Rosh-Haayin, Israel. | Health Technology |
Felsenstein Medical Research Center |